This invention relates to novel 3-aminopyridines of the formula
wherein B
1
, B
2
and R
1
to R
6
are as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compounds are GPBAR1 agonists and can be used as medicaments for the treatment of diseases such as type II diabetes.
This invention relates to novel 3-aminopyridines of the formula
wherein B1, B2 and R1 to R6 are as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compounds are GPBAR1 agonists and can be used as medicaments for the treatment of diseases such as type II diabetes.
[EN] 3-AMINO-PYRIDINES AS GPBAR1 AGONISTS<br/>[FR] 3-AMINOPYRIDINES EN TANT QU'AGONISTES DE GPBAR1
申请人:HOFFMANN LA ROCHE
公开号:WO2012117000A8
公开(公告)日:2013-03-07
US8987307B2
申请人:——
公开号:US8987307B2
公开(公告)日:2015-03-24
[EN] IL-17A MODULATORS<br/>[FR] MODULATEURS DE IL-17A
申请人:SANOFI SA
公开号:WO2021239743A1
公开(公告)日:2021-12-02
The present invention relates to compounds that are IL-17A modulators. The compounds have the structural Formula I defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of diseases or disorders associated with modulation of IL-17A activity.